産婦人科学講座

氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Horie A, Abiko K, Baba T, Sunada M, Kitamura S, Yamanoi K, Horikawa N, Yamaguchi K, Hamanishi J, Kondoh E,
Mandai M. A novel direct approach to the deep uterine vein in laparoscopic radical hysterectomy. J Minim Invasive
Gynecol. 2020:S1553-4650(20)31192-4.
②Huang Z, Kondoh E, Visco Z, Baba T, Matsumura N, Dolan E, Whitaker RS, Konishi I, Fujii S, Berchuck A, Murphy
SK. Targeting dormant ovarian cancer cells in vitro and in an in vivo mouse model of platinum resistance. Mol
Cancer Ther. 2020:molcanther.0119.2020.

馬場長

産婦人科学講座

教授

博士(医学)

婦人科悪性腫瘍③Horikawa N, Abiko K, Matsumura N, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Taki M, Ukita M, Hosoe Y,

腹腔鏡手術

Koshiyama M, Konishi I, Mandai M. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced

ロボット手術myeloid-derived suppressor cell recruitment. Br J Cancer. 2020; 122(1):778–788.
④Zeng X, Baba T, Hamanishi J, Matsumura N, Budiman K, Mise Y, Abiko K, Yamaguchi K, Horikawa N, Huntsman
DG, Mulati K, Kitamura S, Taki M, Murakami R, Hosoe Y, Mandai M. Phosphorylation of STAT1 Serine 727
Enhances Platinum Resistance in Uterine Serous Carcinoma. Int J Cancer. 2019;145(6):1635-1647.
⑤Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K,
Horikawa N, Hosoe Y, Nakamura E, Sugiyama A, Mandai M, Konishi I, Matsumura N.Snail promotes ovarian cancer
progression by recruiting myeloid-derived
suppressor cells via CXCR2 ligand upregulation. Nat Commun. 2018;9(1):1685.
①R Oyama,M Jacobe, A.kihiko,T Sugiyama,R Kikinis, S Pujol.Towards
improved ultrasound-based analysis and 3D visualization of the fetal brain using the 3D Slicer. Ultrasound Obstet
Gynecol 2013; 42:609-10.
② Tanaka S. Oyama R, Fukushima A, Kikuchi A, Sugiyama T. Vector synthesis high-resolution electrocardiography,

小山理恵

産婦人科学講座

特任教授

博士(医学)

周産期学

atrial natriuretic peptide and N-terminal prohormone brain natriuretic peptide for estimation of cardiac load in

産科超音波診断学

pregnancy. J Obstet Gynaecol Res. 2016 Dec;42(12):1644-1651.

女性医学③ Sasaki Y, Kikuchi A, Murai M, Kanasugi T, Isurugi C, Oyama R, Sugiyama T. Fetal goiter associated withpreconception hysterosalpingography using an oil-soluble iodinated contrast medium. Ultrasound Obstet Gynecol.
2017; 49: 275-6.
④Noriko N, Gen H, Hanae K, Miyuki T, Chizuko I, Yuri S, Shinya H, Rie O,Tsukasa B. Evaluation of Normal Fetal
Heart Function by Novel Obstetrics Ultrasound .Clinics Mother Child Health, Vol. 17 Iss. 2 No: 344. 2020
⑤小山理恵.妊娠と授乳. 歯科医師のための内科学. 医歯薬出版株式会社. 2021:p282-289.

産婦人科学講座

氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Shoji T, Takatori E, Kagabu M, Futagami Y, Yokoyama Y, Tokunaga H, Yaegashi N, Ohta T, Watanabe T, Sugiyama
T. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1
genotype in patients with recurrent ovarian cancer (TGCU 104 study) Eur J Gynaecol Oncol 2020; 41: 380-385.
②Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T, Itamochi H. Novel
Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers (Basel).
2021 Dec 4;13(23):6120.

庄子

忠宏

産婦人科学講座

特任准教授

博士(医学)

婦人科腫瘍学
細胞診断学③Shoji T, Kikuchi K, Kogita H, Jonai N, Tomabechi H, Kudoh A, Takatori E, Nagasawa T, Sato S, Kagabu M, Baba T.
New treatment strategy for ovarian cancer with a BRCA gene mutation. Eur J Gynaecol Oncol 2021; 42: 1-9.
④Shoji T, Chie S, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Sato S, Kagabu M, Baba T. Expectations andChallenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer. Medicina 2021, 57(5), 501⑤Shoji T, Enomoto T, Abe M, Okamoto A, Nagasawa T, Oishi T, Nagase S, Mori M, Inokuchi Y, Kamiura S,
Komiyama S, Takeshima N, Sugiyama T. Efficacy and safety of standard of care with/without bevacizumab for
platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese
Gynecologic Oncology Group study JGOG3023. Cancer Sci. 2022 Jan;113(1):240-250.

①Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R. Gastric morphology andimmunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol.
2007 May;31(5):664-72.
②Mikami Y, Kojima A, Kiyokawa T, Manabe T. Ki67 labelling index and p53 status indicate neoplastic nature ofatypical lobular endocervical glandular hyperplasia (ALEGH). Histopathology. 2009 Sep;55(3):362-4.
③Kawakami F, Mikami Y, Kojima A, Ito M, Nishimura R, Manabe T. Diagnostic reproducibility in gastric-type

千葉

淳美

産婦人科学講座

講師

博士(医学)

産婦人科学

mucinous adenocarcinoma of the uterine cervix: validation of novel diagnostic criteria. Histopathology. 2010

婦人科腫瘍学

Mar;56(4):551-3.
④Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, Nishimura R. Absence of high-risk humanpapillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J
Pathol. 2010 Nov;177(5):2169-75.
⑤Kojima A, Muneaki Shimada, Yoshiki Mikami, Shoji Nagao, Nobuhiro Takeshima, Toru Sugiyama, Norihiro
Teramoto, Takako Kiyokawa, Junzo Kigawa, Ryuichiro Nishimura, Sankai Gynecology Study Group.
Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology
Study Group. Int J Gynecol Cancer 2018 Jan;28(1):99-106.

産婦人科学講座

氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Kagabu M, Yoshino N, Saito T, Miura Y, Takeshita R, Murakami K, Kawamura H, Baba T & Sugiyama T. The
efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer
model. International Journal of Clinical Oncology volume 26, pages591–597(2021)②Kagabu M, Nagasawa T, Tatsuki S, Fukagawa Y, Tomabechi H, Takatori E, Kaido Y, Shoji T, Baba T. Comparisonof Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical

利部正裕

産婦人科学講座

講師

博士(医学)

産婦人科学

Cancer: A Retrospective Study. Medicina. 2021 May 29;57(6):548. doi: 10.3390/medicina57060548. PMID:

婦人科腫瘍学34072478

腫瘍免疫学③Kagabu M, Nagasawa T, Sato C, Fukagawa Y, Kawamura H, Tomabechi H, Takemoto S, Shoji T, Baba T.
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Direction. Int J Mol Sci. 2020 Mar
27;21(7):2335. doi: 10.3390/ijms21072335.
④文部科学省科学研究費助成金 挑戦的萌芽研究「課題名：卵巣がんにおける免疫逃避機構改善を目指した新規ウイル
ス療法の開発(代表)」2016-2019年⑤文部科学省科学研究費助成金 基盤研究(C)「課題名：子宮癌肉腫に対する免疫逃避改善を誘導するウイルス療法の開発(代表)」2022-2025年①Isurugi C,Oyama R,Haba G,Sasaki Y,Kaido Y,Kanasugi T,Kikuchi A,Sugiyama T.To visualize the architecture of

周産期
岩動

ちず子

産婦人科学講座

助教

博士（医学）

思春期
女性ヘルスケアplacenta using 3D Slicer software.Placenta 34(10):A12 · October 2013②「胎盤を読む〜胎盤異常の超音波所見と病理組織診〜」第25回日本胎盤学会学術集会 ワークショップ③胎盤異常の診断と管理③基礎と臨床の両側面から見た胎盤学（編）日本胎盤学会、分担執筆④HIVおよび妊婦感染症実施率の全国調査:第34回日本エイズ学会.2020①Nagasawa T, Sugai T, Shoji T, Habano W, Sugiyama T.Molecular Analysis of Single Tumor Glands Using the CryptIsolation Method in Endometrial Carcinomas. Int J Gynecol Cancer. 26:1658-1666. 2016
②Egawa-Takata T, Ueda Y, Ito K, Hori K, Tadahiro S, Nagasawa T, Nishio S, Ushijima K, Koji N, Enomoto T, Kikuchi
A, Honma S, Oishi T, Shimada M, Takei Y, Fujiwara H, Tanabe H, Okamoto A, Nishio Y, Yamada T, Kimura T.
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial
carcinoma. Cancer Sci. May;113(5):1693-1701. 2022

永沢崇幸

産婦人科学講座

助教

博士（医学）

産婦人科学③Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, Oishi T, Ihira K, Kato H, Goto M, Saito M,

婦人科腫瘍学

Taira Y, Yokoyama M, Shoji T, Kondo E, Mori A, Yokoi T, Iwasa-Inoue N, Hirashima Y, Nagasawa T, Takenaka M,
Mikami M, Sugiyama T, Enomoto T. Paclitaxel-carboplatin and bevacizumab combination with maintenancebevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter
phase II trial (JGOG1079). Gynecol Oncol. Jun;165(3):413-419. 2022
④文部科学省科学研究費補助金：「課題名：子宮内膜癌の予後改善を目指した単一癌腺管の分子病理学的解析」2008
年⑤文部科学省科学研究費補助金：「課題名：Molecular pathological analysis of tumor glands using crypt isolation
method in epithelial ovarian carcinomas」20013年

産婦人科学講座

氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Onoue H, Baba T, Koiwa K, Kon M, Ikeda M, Kumagai J. Clinical relevance of endometrial polyps diagnosed byhysteroscopy in 613 infertile women:a retrospective, single-center, cohort study. Obstet Gynecol Int J.
2020;11(3):137-141.
②Onoue H, Baba T, Koiwa K, Kon M, Tsuchiya S, Sato C. Treatment outcomes of intrauterine insemination andpregnancy prognosis factors:a retrospective single-center cohort study. Int J Fam Commun Med. 2020;4(3):78-81.

尾上洋樹

産婦人科学講座

助教

学士（医学）

生殖医療③池田真妃、尾上洋樹、熊谷仁、馬場長. 採卵当日の血清progesterone値と体外受精の妊娠成績について：岩手医学雑内視鏡手術誌.2019;71(2):61-67④Kusumi M, Mitsunami M, Onoue H, Noma M, Matsumura F, Tabata C, Tanaka S, Watanabe N, Kurosawa T,
Fujiwara T, Tsutsumi O. Complete androgen insensitivity syndrome and anti-Mullerian hormone levels before andafter laparoscopic gonadectomy. Gynecol Minim Invasive Ther. 2017 Jul-Sep;6(3):126-128.
⑤Tabata C, Fujiwara T, Sugawa M, Onoue H, Kusumi M, Watanabe N, Kurosawa T, Tsutsumi O. Comparison of
FSH and hMG on ovarian stimulation outcome with a GnRH antagonist protocol in younger and advanced
reproductive age women. Reprod Med Biol. 2015;14:5-9

羽場

厳

産婦人科学講座

助教

博士（医学）

産婦人科疾患全般① Haba G, Oyama R, Kaido Y, Kanasugi T, Isurugi C, Kikuchi A, Sugiyama T: To visualise multiple direction of the

周産期

fetal skeletal dysplasia using 3D Slicer software: a new approach of the fetal MRI. Ultrasound Obstet Gynecol

思春期

44:S326-326, 2014
①Shoji T, Takatori E, Hatayama S, Omi H, Kagabu M, Honda T, Kumagai S, Morohara Y, Miura F, Yoshizaki A,

畑山

伸弥

産婦人科学講座

助教

博士（医学）

産婦人科学

Sugiyama T. Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locallyadvanced cervical cancer. Oncol Lett. 2010 May;1(3):515-519

産婦人科疾患全般
佐藤千絵

産婦人科学講座

助教（任期付）博士（医学）

生殖内分泌
婦人科病理

海道

善隆

産婦人科学講座

助教（任期付）学士（医学）

川村英生

産婦人科学講座

助教（任期付）博士（医学）

産婦人科学講座

助教（任期付）博士（医学）②Sato C, Osakabe M, Nagasawa T, Suzuki H, Itamochi H, Baba T, Sugai T. Global microRNA expression in isolated
cancer glands and surrounding stroma in high-grade serous ovarian carcinoma. Oncol Lett, 20(6),2020.

産婦人科疾患全般
周産期

周産期
花恵

ついた胎盤ポリープ、嵌入胎盤の1例. 岩手医学雑誌, 58(1), 22-64, 2018.

婦人科腫瘍

産婦人科疾患全般
川村①佐藤千絵, 畑山伸弥, 川村英生, 土屋詩乃, 菅原千裕, 小笠原敏浩, 刑部光正, 菅井有, 菊池昭彦. 経腟分娩後に確定診断が女性ヘルスケア（思春期、更年期、
アスリート）①川村花恵.トレハロース誘導体の粘膜アジュバント活性：経鼻免疫を行ったマウスでの液性免疫増強効果の検討.岩手
医学雑誌, 68(2), 81-95, 2016.
②新沼花恵、苫米地 英俊、秋元 義弘、佐藤昌之、菊池権恵、西山 理、酒井 敏彰、上田 寛修.卵巣静脈に留置された下大静脈フィルターを、術中に卵巣静脈末梢側から回収し得た一例.岩手県立病院医学会雑誌.54(1) 2014
③令和2年度科学研究費助成事業

若手研究「課題名

拡散尖度画像を用いた産後うつ病の脳内変化の解明と、新たな診断手法としての応用」①Terata M,Kikuchi A,Kanasugi T, Oyama R, Fukushima A,Sugiyama T.Prenatal diagnosis of parasitic conjoined寺田幸

産婦人科学講座

助教（任期付）博士（医学）

産婦人科疾患全般

twins with three-dimensional ultrasound.Congenital Anomalies 53(3):131-3·2013

周産期②Terata M, Nakai K, Fukushima A, Itoh M, Kikuchi A, Sugiyama T. Detection of peripartum myocardial burden by

女性ヘルスケアvector-projected 187 channel electrocardiography and serum NT-proBNP. Int Heart J. 2013;54(3):140-145.
doi:10.1536/ihj.54.140

産婦人科学講座

氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Chiba Y, Sudo K, Kojima Y, Okuma H, Kohsaka S, Machida R, Ichimura M, Anjo K, Kurishita K, Okita N,
Nakamura K, Kinoshita I, Takahashi M, Matsubara J, Kusaba H, Yonemori K, Takahashi M. A multicenter
investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast
growth factor receptor (FGFR) gene alteration: FORTUNE trial. BMC Cancer. 2022 Aug 9;22(1):869.
②Chiba Y, Nishikawa T, Yonemori K. Current Status and Future Development of Anti-Cancer Drugs in Rare
Gynecologic Cancers-The Rise of Anti-HER2 Therapy. Gan To Kagaku Ryoho. 2021 Feb;48(2):200-205.

千葉洋平

産婦人科学講座

助教（任期付）博士（医学）

婦人科腫瘍学
がん薬物療法③Chiba Y, Sato S, Itamochi H, Suga Y, Fukagawa T, Oumi N, Oishi T, Harada T, Sugai T, Sugiyama T. Establishment
and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Hum Cell. 2017 Apr;30(2):140-148.
④Chiba Y, Sato S, Itamochi H, Yoshino N, Fukagawa D, Kawamura H, Suga Y, Kojima-Chiba A, Muraki Y, Sugai T,
Sugiyama T. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma
Cell Lines Induced by Cisplatin: A Potential Treatment Strategy. Int J Gynecol Cancer. 2017 Oct;27(8):1666-1674.
⑤Sato S, Itamochi H, Oumi N, Chiba Y, Oishi T, Shimada M, Sato S, Chikumi J, Nonaka M, Kudoh A, Komatsu H,
Harada T, Sugiyama T. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC2, with loss of ARID1A expression. Hum Cell. 2016 Oct;29(4):181-7.

齋藤達憲

産婦人科学講座

助教（任期付）髙取恵里子

産婦人科学講座

助教（任期付）村上一行

産婦人科学講座

助教（任期付）